Literature DB >> 20804809

Quality of life and cognitive dysfunction in people with schizophrenia.

Yoshinori Ueoka1, Masahito Tomotake, Tsunehiko Tanaka, Yasuhiro Kaneda, Kyoko Taniguchi, Masahito Nakataki, Shusuke Numata, Shinya Tayoshi, Ken Yamauchi, Satsuki Sumitani, Takashi Ohmori, Shu-ichi Ueno, Tetsuro Ohmori.   

Abstract

The main purpose of the present study was to examine the relationship between quality of life (QOL) and cognitive dysfunction in schizophrenia. Subjects were 61 stabilized outpatients. Quality of life and cognitive function were assessed using the Quality of Life Scale (QLS) and the Brief Assessment of Cognition in Schizophrenia (BACS), respectively. Clinical symptoms were evaluated with the Positive and Negative Syndrome Scale (PANSS) and the Calgary Depression Scale for Schizophrenia (CDSS). The BACS composite score and the BACS Verbal memory score were positively correlated with the QLS total score and two subscales. The BACS Attention and speed of information processing score had positive correlation with the QLS total and all the subscales scores. The PANSS Positive and Negative syndrome scores also had significant correlations with the QLS total score and all of the subscales. In addition, the CDSS score was negatively correlated with the QLS total score and some of the subscales. Stepwise regression analysis showed that the BACS Attention and speed of information processing score was an independent predictor of the QLS total score but it was less associated with the QLS than the PANSS Negative syndrome score and the CDSS score. The results suggest that negative and depressive symptoms are important factors on patients' QOL and also support the view that cognitive performance provides a determinant of QOL in patients with schizophrenia.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20804809     DOI: 10.1016/j.pnpbp.2010.08.018

Source DB:  PubMed          Journal:  Prog Neuropsychopharmacol Biol Psychiatry        ISSN: 0278-5846            Impact factor:   5.067


  14 in total

1.  Quality of life and adverse effects of olanzapine versus risperidone therapy in patients with schizophrenia.

Authors:  Katarina Melo Chaves; Antoni Serrano-Blanco; Susana Barbosa Ribeiro; Luiz Alberto Lira Soares; Gerlane Coelho Bernardo Guerra; Maria do Socorro Costa Feitosa Alves; Raimundo Fernandes de Araújo Júnior; Vanessa de Paula Soares Rachetti; Antônio Filgueira Júnior; Aurigena Antunes de Araújo
Journal:  Psychiatr Q       Date:  2013-03

2.  Cardiovascular Pharmacogenomics and Cognitive Function in Patients with Schizophrenia.

Authors:  Kristen M Ward; A Zarina Kraal; Stephanie A Flowers; Vicki L Ellingrod
Journal:  Pharmacotherapy       Date:  2017-08-02       Impact factor: 4.705

3.  Sildenafil adjunctive therapy to risperidone in the treatment of the negative symptoms of schizophrenia: a double-blind randomized placebo-controlled trial.

Authors:  Shahin Akhondzadeh; Raofeh Ghayyoumi; Farzin Rezaei; Bahman Salehi; Amir-Hossein Modabbernia; Azad Maroufi; Gholam-Reza Esfandiari; Mehrangiz Naderi; Fariba Ghebleh; Mina Tabrizi; Shams-Ali Rezazadeh
Journal:  Psychopharmacology (Berl)       Date:  2010-10-15       Impact factor: 4.530

4.  Screening for cognitive impairment in schizophrenia: Psychometric properties of the German version of the Screen for Cognitive Impairment in Psychiatry (SCIP-G).

Authors:  Gabriele Sachs; Iris Lasser; Scot E Purdon; Andreas Erfurth
Journal:  Schizophr Res Cogn       Date:  2021-05-12

5.  Relationships between brain-derived neurotrophic factor, clinical symptoms, and decision-making in chronic schizophrenia: data from the Iowa Gambling Task.

Authors:  Hikaru Hori; Reiji Yoshimura; Asuka Katsuki; Kiyokazu Atake; Jun Nakamura
Journal:  Front Behav Neurosci       Date:  2014-12-04       Impact factor: 3.558

6.  Relationship between social and cognitive functions in people with schizophrenia.

Authors:  Takeo Tominaga; Masahito Tomotake; Tomoya Takeda; Yoshinori Ueoka; Tsunehiko Tanaka; Shin-Ya Watanabe; Naomi Kameoka; Masahito Nakataki; Shusuke Numata; Yumiko Izaki; Satsuki Sumitani; Hiroko Kubo; Yasuhiro Kaneda; Tetsuro Ohmori
Journal:  Neuropsychiatr Dis Treat       Date:  2018-08-30       Impact factor: 2.570

7.  Negative and positive self-thoughts predict subjective quality of life in people with schizophrenia.

Authors:  Tomoya Takeda; Masahito Nakataki; Masashi Ohta; Sayo Hamatani; Kanae Matsuura; Reona Yoshida; Naomi Kameoka; Takeo Tominaga; Hidehiro Umehara; Makoto Kinoshita; Shinya Watanabe; Shusuke Numata; Satsuki Sumitani; Tetsuro Ohmori
Journal:  Neuropsychiatr Dis Treat       Date:  2019-01-21       Impact factor: 2.570

8.  Neurocognitive Functioning in Schizophrenia and Bipolar Disorder: Clarifying Concepts of Diagnostic Dichotomy vs. Continuum.

Authors:  Carissa N Kuswanto; Min Y Sum; Kang Sim
Journal:  Front Psychiatry       Date:  2013-12-05       Impact factor: 4.157

9.  Why it is time to develop the use of cognitive event-related potentials in the treatment of psychiatric diseases.

Authors:  Salvatore Campanella
Journal:  Neuropsychiatr Dis Treat       Date:  2013-11-28       Impact factor: 2.570

10.  Preclinical profile of ITI-214, an inhibitor of phosphodiesterase 1, for enhancement of memory performance in rats.

Authors:  Gretchen L Snyder; Jos Prickaerts; Marie-Louise Wadenberg; Lei Zhang; Hailin Zheng; Wei Yao; Sven Akkerman; Hongwen Zhu; Joseph P Hendrick; Kimberly E Vanover; Robert Davis; Peng Li; Sharon Mates; Lawrence P Wennogle
Journal:  Psychopharmacology (Berl)       Date:  2016-06-24       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.